This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Aetiology

Authoring team

Analgesic abuse nephropathy has been linked with chronic high intake of the following drugs:

  • paracetamol (acetaminophen)
  • phenacetin - this drug was withdrawn in 1966
  • aspirin

However non-steroidal anti-inflammatory drugs (NSAIDs) have become the most common cause of drug induced damage in clinical practice (1).

Narcotic analgesics are not directly nephrotoxic and therefore do not themselves result in analgesic-induced renal damage (2).

Caffeine is also found in many preparations. This agent and similar centrally acting agents may promote habituation and lead to the consumption of increasing doses of analgesics (3).

Notes (4):

  • chronic analgesic nephropathy, particularly chronic interstitial nephritis and renal papillary necrosis, results from daily use for many years of mixtures containing at least two analgesics and caffeine or dependence-inducing drugs
  • computed tomography scan can accurately diagnose this disease even in the absence of reliable information on previous analgesic use
  • occasional to moderate regular use of aspirin and nonsteroidal anti-inflammatory drugs is without renal risk when renal function is normal
  • paracetamol use is less clear although the risk is not great.
  • continued use of non-phenacetin-combined analgesics with or without nonsteroidal anti-inflammatory drugs is associated with faster progression toward renal impairment.

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.